Skip to main content

Table 2 The AUC, sensitivity and specificity of miRNA-based biomarkers for detection of pancreatic cancer

From: Advance in microRNA as a potential biomarker for early detection of pancreatic cancer

Item Drived from AUC Sensitivity (%) Specificity (%) Reference
PCa vs. Normal PCa vs. CP PCa vs. Normal PCa vs. CP PCa vs. Normal PCa vs. CP
miR-20a, 21, 24, 25, 99a, 185, 191 Serum 0.992 89 100 [13]
miR-10b, 155, 106b, 30c, 212 Plasma >0.90 95 100 [14]
Bile 96 100
miR-21, 210, 155, 196a Plasma 0.82 64 89 [15]
CA19-9 Serum 0.903 0.897 81.2 81.2 100.0 89.0 [17]
miR-16, 196a, Plasma 0.895 0.790 87.0 75.4 73.5 66.4
miR-16+miR-196a+CA19-9 - 0.979 0.956 92.0 88.4 95.6 96.3
PaCIC marker Serum - 0.96 0.86 [18]
miR-1246, 4644, 3976, 4306 Serum - 0.81 0.94
PaCIC marker + miR-1246, 4644, 3976, 4306 Serum - 1.00 0.80
  1. Serum miR-20a, 21, 24, 25, 99a, 185 and 191 were derived from 197 PCa cases and 158 age- and sex-matched cancer-free controls. MiR-10b, 155, 106b, 30c and 212 were derived from patients (n = 215) with treatment-naive PDAC (n = 77), CP with bile/pancreatic duct pathology (n = 67), and controls (n = 71). The plasma levels of miR-21, 210, 155, 196a were interrogated in 49 PCa and 36 normal healthy individuals. Plasma miR-16, 196a and CA19-9 were extracted from 140 PCa patients, 111 CP patients and 68 normal controls. PaCIC marker and miR-1246, 4644, 3976, 4306 were collected from 20 healthy donors, 131 PCa, 25 CP, 22 benign pancreatic tumors, 12 nonPCa. PCa pancreatic cancer, CP chronic pancreatitis, AUC area under the curve, − No data was available in the instances